Literature DB >> 2496994

Predictive value of the presence of P24 antigen in persons with antibodies to human immunodeficiency virus in Spain.

M Leal1, J A Pineda, E J Calderón, C Rey, E Lissen.   

Abstract

In a prospective study of 37 individuals in Spain who did not have AIDS or AIDS-related complex but were positive for antibody to HIV, 164 sequentially taken serum samples were tested for the presence of the p24 antigen of HIV. Six of the subjects were antigenemic at entry to the study and five of the remaining 31 subjects seroconverted for HIV antigen during follow-up. Six (55%) of the 11 antigenemic patients but none of those without antigenemia developed AIDS. The interval from the time of first detection of HIV antigen to the diagnosis of AIDS varied greatly. The results confirm that individuals with HIV antigenemia run a significantly higher risk of developing AIDS.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2496994     DOI: 10.1007/bf01965269

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  22 in total

1.  Diagnostic significance of quantitative determination of HIV antibody specific for envelope and core proteins.

Authors:  G G Frösner; V Erfle; W Mellert; R Hehlmann
Journal:  Lancet       Date:  1987-01-17       Impact factor: 79.321

2.  Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenaemia.

Authors:  F de Wolf; J Goudsmit; D A Paul; J M Lange; C Hooijkaas; P Schellekens; R A Coutinho; J van der Noordaa
Journal:  Br Med J (Clin Res Ed)       Date:  1987-09-05

3.  Temporal relation of antigenaemia and loss of antibodies to core antigens to development of clinical disease in HIV infection.

Authors:  C Pedersen; C M Nielsen; B F Vestergaard; J Gerstoft; K Krogsgaard; J O Nielsen
Journal:  Br Med J (Clin Res Ed)       Date:  1987-09-05

4.  Acute infection with the human immunodeficiency virus (HIV) associated with acute brachial neuritis and exanthematous rash.

Authors:  L H Calabrese; M R Proffitt; K H Levin; B Yen-Lieberman; C Starkey
Journal:  Ann Intern Med       Date:  1987-12       Impact factor: 25.391

5.  Long-term evaluation of HIV antigen and antibodies to p24 and gp41 in patients with hemophilia. Potential clinical importance.

Authors:  J P Allain; Y Laurian; D A Paul; F Verroust; M Leuther; C Gazengel; D Senn; M J Larrieu; C Bosser
Journal:  N Engl J Med       Date:  1987-10-29       Impact factor: 91.245

6.  Diagnosis of human immunodeficiency virus infection in seronegative homosexuals presenting with an acute viral syndrome.

Authors:  H A Kessler; B Blaauw; J Spear; D A Paul; L A Falk; A Landay
Journal:  JAMA       Date:  1987-09-04       Impact factor: 56.272

7.  Detection of HIV antigen and specific antibodies to HIV core and envelope proteins in sera of patients with HIV infection.

Authors:  Y Z Cao; F Valentine; S Hojvat; J P Allain; P Rubinstein; M Mirabile; S Czelusniak; M Leuther; L Baker; A E Friedman-Kien
Journal:  Blood       Date:  1987-08       Impact factor: 22.113

8.  Human immunodeficiency virus infection in two cohorts of homosexual men: neutralising sera and association of anti-gag antibody with prognosis.

Authors:  J N Weber; P R Clapham; R A Weiss; D Parker; C Roberts; J Duncan; I Weller; C Carne; R S Tedder; A J Pinching
Journal:  Lancet       Date:  1987-01-17       Impact factor: 79.321

9.  Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort.

Authors:  A R Moss; P Bacchetti; D Osmond; W Krampf; R E Chaisson; D Stites; J Wilber; J P Allain; J Carlson
Journal:  Br Med J (Clin Res Ed)       Date:  1988-03-12

10.  Human immunodeficiency virus (HIV) antigenemia (p24) in the acquired immunodeficiency syndrome (AIDS) and the effect of treatment with zidovudine (AZT).

Authors:  G G Jackson; D A Paul; L A Falk; M Rubenis; J C Despotes; D Mack; M Knigge; E E Emeson
Journal:  Ann Intern Med       Date:  1988-02       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.